{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Melanotan Ii",
    "short_name": "Melanotan II",
    "aliases": [
      "MT2"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Melanotan II is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Despite lack of regulatory approval, Melanotan II is widely sold as a research chemical and is used by humans for cosmetic tanning and related melanocortin effects. Product purity, dose labeling, and formulation consistency vary substantially in the gray/illicit market, which increases uncertainty and risk."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "mechanistic_only",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Key risks are driven by: (1) unapproved/non-standardized products in real-world use, (2) melanocortin receptor agonism producing systemic effects (e.g., nausea, flushing, blood pressure changes), (3) reported severe adverse events in case literature (e.g., priapism), and (4) concern signals around changing nevi/pigmentation and possible melanoma association in reports. Evidence includes human interventional pharmacology plus observational and case reports; uncertainty remains high.",
      "developmental_systems_of_concern": [
        "melanocortin",
        "hormonal",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Melanotan II is a synthetic melanocortin peptide designed to activate melanocortin receptors (notably MC1R) to increase melanin production, and it can also affect other melanocortin pathways linked to sexual function and appetite. Human clinical work exists for specific effects, but most real-world tanning use occurs outside regulated medical products, increasing variability and safety uncertainty.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3",
            "E4",
            "E5"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "",
          "unit": "",
          "min": null,
          "max": null,
          "frequency": "",
          "duration": "",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "",
        "published_date": "",
        "evidence_grade": "mechanistic_only",
        "notes": ""
      },
      {
        "id": "E2",
        "source_id": "PMID:16412534",
        "source_type": "review",
        "evidence_grade": "human_observational",
        "title": "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.",
        "year": 2006,
        "url": "https://pubmed.ncbi.nlm.nih.gov/16412534/",
        "notes": "Use to bound harms and uncertainty; not endorsement."
      },
      {
        "id": "E3",
        "source_id": "PMID:40210573",
        "source_type": "journal_article",
        "evidence_grade": "human_observational",
        "title": "Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?",
        "year": 2025,
        "url": "https://pubmed.ncbi.nlm.nih.gov/40210573/",
        "notes": "Adverse-event context only; case-level evidence."
      },
      {
        "id": "E4",
        "source_id": "E4",
        "source_type": "regulatory",
        "evidence_grade": "mechanistic_only",
        "title": "Regulatory/health advisory on unapproved melanotan products (public safety communication)",
        "year": 0,
        "url": "",
        "notes": "High-level safety framing; not a clinical study."
      },
      {
        "id": "E5",
        "title": "Melanoma in-situ associated with Melanotan II use (case report PDF)",
        "source_type": "case_report",
        "source_id": "scientificliterature.org:Casereports-20-147",
        "evidence_grade": "human_observational",
        "year": 2019,
        "url": "https://scientificliterature.org/Casereports/Casereports-20-147.pdf",
        "notes": "Association signal only (case report); cannot establish causality; useful for uncertainty/risk disclosure."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Melanotan II",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T13:32:56.641931+00:00",
        "change_type": "content_update",
        "summary": "Added conservative evidence scaffold and linked overview refs (no instructions).",
        "detail": "Inserted mechanistic + observational + adverse-event + regulatory placeholders to bound uncertainty and harms. No dosing/protocol language added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4"
        ]
      },
      {
        "date": "2026-01-19T15:43:16.140262+00:00",
        "change_type": "content_update",
        "summary": "Filled Melanotan II core identity + risk notes and linked conservative evidence refs (no instructions).",
        "detail": "Removed placeholder language from required fields and added a minimal, conservative evidence set (human interventional + observational/case + regulator warning). No protocol or dosing guidance added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4",
          "E5"
        ]
      },
      {
        "date": "2026-01-19T16:01:39.283793+00:00",
        "change_type": "content_update",
        "summary": "Filled Melanotan II core identity + risk notes and linked conservative evidence refs (no instructions).",
        "detail": "Removed placeholder language from required fields and added a minimal, conservative evidence set (human interventional + observational/case + regulator warning). No protocol or dosing guidance added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4",
          "E5"
        ]
      },
      {
        "date": "2026-01-19T16:47:16.401818+00:00",
        "change_type": "content_update",
        "summary": "Evidence finalization: replaced PubMed placeholders with specific PMIDs/years (no instructions).",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_skin_cosmetic"
      ]
    },
    "slug": "melanotan-ii"
  },
  "canonical_name": "Melanotan Ii"
}
